There is substantial heterogeneity in PSMA expression and uptake on PSMA PET in the metastatic castration-resistant prostate cancer setting, which narrows the scope of who might benefit from targeted radioligand therapy.18,24-26 In the current study, we used a more liberal PET selection strategy than previous studies of 177Lu-PSMA-617 (VISION and PRINCE) and observed anti-tumour activity in lesions with low or negative uptake. The gene discussed is FOLH1; the disease is prostate cancer.